Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M. Clark, Daniel Skovronsky, Abhinay D. Joshi et al.|The Lancet Neurology|2012Cited by 846
Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingKeith A. Johnson, Reisa A. Sperling, Christopher Gidicsin et al.|Alzheimer s & Dementia|2013Cited by 265
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter studyMichael J. Pontecorvo, P. Murali Doraiswamy, Reisa A. Sperling et al.|Molecular Psychiatry|2014Cited by 196
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individualsReisa A. Sperling, Michael J. Pontecorvo, Keith A. Johnson et al.|Neurobiology of Aging|2012Cited by 127
Increased peptidylarginine deiminases expression during the macrophage differentiation and participated inflammatory responsesNing‐Sheng Lai, Ming‐Chi Lu|Arthritis Research & Therapy|2019Cited by 26